Effects of addition of Armodafinil on the tolerability and efficacy for cognition of atypical antipsychotic drugs in patients with schizophrenia or schizoaffective disorder

Trial Profile

Effects of addition of Armodafinil on the tolerability and efficacy for cognition of atypical antipsychotic drugs in patients with schizophrenia or schizoaffective disorder

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Dec 2016

At a glance

  • Drugs Armodafinil (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Aug 2011 Results published in the Schizophrenia Research.
    • 02 Mar 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
    • 02 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top